Overview

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.
Phase:
Phase 3
Details
Lead Sponsor:
Alain Kaelin
Collaborator:
Clinical Trial Unit Ente Ospedaliero Cantonale
Treatments:
Botulinum Toxins, Type A
incobotulinumtoxinA